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A phenome-wide association and Mendelian
Randomisation study of polygenic risk for
depression in UK Biobank
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Andrew M. McIntosh 1,3,4,153✉
Depression is a leading cause of worldwide disability but there remains considerable
uncertainty regarding its neural and behavioural associations. Here, using non-overlapping
Psychiatric Genomics Consortium (PGC) datasets as a reference, we estimate polygenic risk
scores for depression (depression-PRS) in a discovery (N= 10,674) and replication (N=
11,214) imaging sample from UK Biobank. We report 77 traits that are significantly associated
with depression-PRS, in both discovery and replication analyses. Mendelian Randomisation
analysis supports a potential causal effect of liability to depression on brain white matter
microstructure (β: 0.125 to 0.868, pFDR < 0.043). Several behavioural traits are also asso-
ciated with depression-PRS (β: 0.014 to 0.180, pFDR: 0.049 to 1.28 × 10−14) and we find a
significant and positive interaction between depression-PRS and adverse environmental
exposures on mental health outcomes. This study reveals replicable associations between
depression-PRS and white matter microstructure. Our results indicate that white matter
microstructure differences may be a causal consequence of liability to depression.
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Major depression is the leading contributor to the globalburden of disease1, due to its high prevalence2, disablingconsequences2 and partial treatment response3. Major
depression is heritable (h2= 37%)4 and recent genome-wide
association studies (GWAS) by Wray et al.5 and Howard et al.6 for
the Psychiatric Genomics Consortium (PGC) have identified 44
and 102 risk-associated genetic variants, respectively. Although
each single genetic variant contributes very little to disease liabi-
lity, the genetic risk scores based on the additive effect of common
genetic variants over the whole genome, i.e. polygenic risk scores
(PRS), can account for a significant proportion of phenotypic
variance7. The latest GWAS of depression now provides the ability
to more precisely estimate polygenic risk of depression in inde-
pendent samples6 and thereby identify traits whose genetic
architecture is shared with major depression using PRS.
Major depression is phenotypically correlated with many beha-
viours, brain structure and function measures, cognitive domains
and physical conditions8–13. It is important to investigate the
associations between the genetic predisposition to major depression
and these phenotypes, to help identify shared causal risk factors,
mechanisms and the causal consequences of major depression14.
Until recently, however, this approach has received relatively little
attention owing to a lack of data resources with the appropriate
scale and coverage of genetic, behavioural and neuroimaging traits
to test for these associations with sufficient statistical power15–17.
A phenome-wide association study (PheWAS) aims to identify
multiple phenotypes associated with a single genetic risk score or
genotype. Unlike studies that examine associations between a
single trait and genetic risk scores, PheWAS are less constrained
by prior assumptions. This is particularly important in situations
where we currently have an incomplete understanding of disease
mechanisms. Genotype-based PheWAS approaches also have the
considerable advantage that they are based on robust biological
knowledge that is fixed from birth and therefore less susceptible
to confounding and reverse causality.
The present study uses large data sets for both depression-PRS
generation and a wide range of phenotypes, including neuroi-
maging. Depression-PRS are generated using summary statistics
from the most recent meta-analysis combining the PGC, UK
Biobank and 23andMe (N= 0.8 million)6. A PheWAS approach
is used to estimate the effect and significance of associations
between depression-PRS and other behavioural, cognitive and
neuroimaging traits. A PheWAS is conducted on the latest neu-
roimaging data releases from the UK Biobank imaging project18
that includes a discovery sample of 10,674 people, and a repli-
cation sample of 11,214 people (21,888 individuals in total). The
UK Biobank imaging project is a large-scale data set containing
both genetic and cross-modality neuroimaging data. A total of 77
traits are associated with polygenic risk of depression both in
discovery and replication samples. Where depression-PRS are
associated with neuroimaging phenotypes, we additionally test
whether this is a potential causal consequence of depression or,
conversely, whether neuroimaging measures have a causal effect
on depression, using Mendelian Randomisation (MR) and
structural equational modelling (SEM). The findings suggest that
variation in white matter microstructure is a consequence of
depression. We also test for the presence of gene-by-environment
interactions using measures of early-life risk factors and socio-
demographic variables available in UK Biobank19,20, which show
larger effects of polygenic risk of depression on psychiatric con-
ditions when participants are exposed to adverse environments.
Results
PheWAS. We found that 100 phenotypes (67 behavioural and 33
neuroimaging) out of 552 examined (209 behavioural and 343
neuroimaging) in the discovery sample showed significant asso-
ciations with depression-PRS at a minimum of four p thresholds
after FDR (false discovery rate) correction for multiple compar-
isons (absolute β: 0.014–0.341, β are standardised regression
coefficients throughout, pFDR for linear regression: 0.050–3.61 ×
10−31). There were 37 phenotypes that remained significant after
Bonferroni correction. However, due to correlation between the
phenotypes tested, Bonferroni correction is likely to be overly
conservative. Thresholds for both FDR and Bonferroni correc-
tions are shown in Supplementary Fig. 1.
Overall results for depression-PRS of representative p thresh-
olds of 1 and 0.01 are presented in Fig. 1. These two thresholds
were selected since pT < 1 and pT < 0.01 showed the largest effect
sizes in behavioural traits and neuroimaging phenotypes,
respectively (see Fig. 2 and Supplementary Fig. 1). Results for
other thresholds can be found in Supplementary Fig. 1,
Supplementary Table 1 and Supplementary Data 1-2.
All of the 100 variables showed an identical direction of effect
in the replication sample (Fig. 3, Supplementary Figs. 2 and 3 and
Supplementary Data 2 and 3). After multiple comparison
correction, 77 traits showed associations with depression-PRS at
a minimum of four p thresholds in the replication sample (51
behavioural and 26 neuroimaging). Within these traits, 23
remained significant after Bonferroni correction. In total, 77%
findings were replicated; the highest replication rates were seen
for white matter microstructure (92.3%), mental health variables
(81.3%) and physical measures (76%), see Supplementary Figs. 2
and 3. There was no significant interaction between magnetic
resonance imaging (MRI) site and depression-PRS on any of the
traits (pcor > 0.431, see Supplementary Fig. 4, Supplementary
Data 4). Results for meta-analysis combining the two samples can
be found in Supplementary Figs. 5 and 6 and Supplementary
Data 5.
Significant associations that were found in both the discovery
and replication data sets are reported below; the βs provided are
from the discovery analysis. A complete list of all results is
presented in Supplementary Data 2 and 3.
For the associations between depression-PRS and definitions
for depression and symptomology, higher depression-PRS were
associated with the presence of depression based on all three
definitions, including broad depression (β: 0.154–0.300, pFDR
for linear regression: 3.93 × 10−9–3.61 × 10−31), probable
depression (β: 0.174–0.341, pFDR for linear regression: 1.14 ×
10−6–1.52 × 10−23), and Composite International Diagnostic
Interview (CIDI) depression (β: 0.121–0.261, pFDR for linear
regression: 3.08 × 10−4–1.18 × 10−17). Significant associations
were also found between depression-PRS and depressive
symptoms, assessed by PHQ-4 (Patient Health Questionnaire)
and CIDI questionnaires, and other self-reported psychological
traits, including self-harm, subjective well-being, reported
feeling of not worth living and neuroticism (absolute β:
0.027–0.339, pFDR for linear regression: 0.045–8.84 × 10−30).
Associations were found between depression-PRS and white
matter microstructure. Higher depression-PRS were in general
associated with decreased white matter microstructural integrity.
First, by looking at the classic microstructural measures of
fractional anisotropy (FA) and mean diffusivity (MD): globally
lower FA and higher MD (absolute β: 0.027–0.038, pFDR for linear
regression: 0.037–6.90 × 10−4) were associated with higher
depression-PRS. Lower microstructural integrity was also found
in the general measures of FA and MD for two subsets of white
matter tracts, the association fibres (absolute β: 0.029–0.040, pFDR
for linear regression: 0.024–6.05 × 10−4) and thalamic radiations
(absolute β: 0.025–0.036, pFDR for linear regression: 0.036–2.70 ×
10−3). For each individual tract (Figs. 2 and 4), higher depression-
PRS were associated with decreased FA in inferior fronto-occipital
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fasciculus, inferior longitudinal fasciculus, posterior thalamic
radiation and superior longitudinal fasciculus (SLF) (β: −0.025
to −0.032, pFDR for linear regression: 0.050–5.78 × 10−3) and
increased MD in anterior thalamic radiation (ATR), cingulate
gyrus part of cingulum, inferior fronto-occipital fasciculus, SLF
and superior thalamic radiation (β: 0.023–0.042, pFDR for linear
regression: 0.040–6.95 × 10−5). All associations found for neurite
orientation dispersion and density imaging measures were in
intra-cellular volume fraction (ICVF; an index reflecting neurite
density, β: −0.025 to −0.044, pFDR for linear regression:
0.047–1.74 × 10−4). General variance of ICVF in the association
fibre subset was negatively associated with depression-PRS (β:
−0.028 to −0.039, pFDR for linear regression: 0.036–1.13 × 10−3).
For tracts, lower ICVF was correlated with higher depression-PRS
in similar regions found for FA and MD, in acoustic radiation,
cingulate gyrus part of cingulum, inferior fronto-occipital
fasciculus, SLF and uncinate fasciculus (β: −0.025 to −0.043,
pFDR for linear regression: 0.043–2.10 × 10−4).
Depression-PRS were also found associated with resting-state
fluctuation amplitude. Associations were found between
depression-PRS and resting-state fluctuation amplitude of low-
frequency signal (β: 0.027–0.043, pFDR: 0.037–2.03 × 10−4) in the
discovery sample (Figs. 2 and 4). A full list of report is presented
in Supplementary Data 2.
In brief, higher depression-PRS were associated with lower
fluctuation amplitude in anterior cingulate gyrus (peak coordina-
tion: −10, 54, 2; cluster size: 7065), bilateral postcentral gyrus
(peak coordination: −44, −30, 46 and 44, −24, 40 for left and
right hemispheres, respectively; cluster sizes: 2781 and 1619),
bilateral insula (peak coordination: −38, −4, 16 and 30, 18, −16
for left and right hemispheres, respectively; cluster sizes: 963 and
308), bilateral orbital part of inferior frontal gyrus (peak
coordination: −34, 34, −12 and 32, 36, −10 for left and right
hemispheres, respectively; cluster sizes: 154 and 171) and left
superior frontal lobe (peak coordination: −18, 32, 38; cluster size:
124). These regions are largely contained within the salience,
executive control and sensorimotor networks (Supplementary
Table 2)15,21.
Finally, depression-PRS were found associated with sleep
problems, smoking and poor physical health. In the category of
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Fig. 1 Significance plot for all phenotypes for depression-PRS at p threshold (pT) < 1 and pT < 0.01. The x axes represent phenotypes, and the y axes
represent the −log10 of uncorrected p values of two-sided test for linear regression between depression-PRS and each of the phenotype. Each dot
represents one phenotype, and the colours indicate their according categories. The dashed lines indicate the threshold to survive FDR correction. FDR
correction was applied over all the traits and all depression-PRS (see “Methods”). From left to right on the x axis, categories were shown by the sequence
of mental health measure, sociodemographics, early-life risk factor, lifestyle measure, physical measure, cognitive ability, intracranial/subcortical volume,
white matter microstructure, white matter hyperintensity, resting-state functional connectivity and resting-state fluctuation amplitude. Representative top
findings are annotated in the figure. SN salience network, ECN executive control network, SMN sensorimotor network, FA fractional anisotropy, MD (for
white matter microstructure) mean diffusivity, ICVF intra-cellular volume fraction, AF association fibres, FMi forceps minor, SLF superior longitudinal
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lifestyle measures, reporting of sleep problems (e.g. too much sleep
or insomnia) (absolute β: 0.034–0.180, pFDR for linear regression:
0.043–8.26 × 10−9) and smoking behaviours (absolute β:
0.044–0.105, pFDR for linear regression: 2.28 × 10−3–3.74 × 10−8)
were found to be significantly positively associated with
depression-PRS.
Physical health items associated with depression-PRS can be
summarised as the following four categories: (1) self-reported overall
health rating and conditions of long-standing illnesses (absolute β:
0.040–0.129, pFDR for linear regression: 4.38 × 10−3–1.49 × 10−13),
(2) recent pains and on-going treatment for pain (absolute β:
0.083–0.163, pFDR for linear regression: 6.30 × 10−4–1.28 × 10−14),
(3) cardiovascular/heart problems (absolute β: 0.066–0.112, pFDR for
linear regression: 0.027–1.97 × 10−5), and (4) body mass and weight
change compared to 1 year ago (absolute β: 0.014–0.042, pFDR for
linear regression: 0.046–5.00 × 10−6).
Bidirectional MR on imaging phenotypes and depression. A
significant and potentially causal effect of depression was found
on lower microstructural integrity in four white matter micro-
structural measures and lower resting-state fluctuation amplitude
in the Salience Network (Node 14). For these phenotypes, the
effect from depression were shown using at least two MR
methods after FDR correction (Fig. 5, Supplementary Data 6 and
7 and Supplementary Figs. 7–11). The neuroimaging phenotypes
include (β and pFDR reported for significant effects): global gMD
(gMD-Total; β: 0.125–0.724, pFDR for MR: 0.041–0.022, sig-
nificant for all three MR methods), gMD in thalamic radiations
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Fig. 2 Heatmap for the traits that were significantly associated with depression-PRS. The shown traits were significantly associated with depression-PRS
at a minimum of four p thresholds for depression-PRS. Shades of cells indicate the standardised effect sizes (β) for the linear regression between
depression-PRS and each phenotype. A larger effect size was shown by a darker colour. Cells with an asterisk were significant after FDR correction.
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(gMD-TR; β: 0.131–0.527, pFDR for MR: 0.050–0.010, significant
for all three MR methods), ICVF in SLF (tICVF-SLF; β: −0.159 to
−0.926, pFDR for MR: 0.023–0.015, inverse-variance weighted
estimator (IVW) and MR-Egger) and forceps major (tICVF-FMa;
β: −0.160 to −0.792, pFDR for MR: 0.040–0.023, IVW and MR-
Egger), and the resting-state fluctuation amplitude in the Salience
Network (amp-N14; β: −0.130 to −0.177, pFDR for MR:
0.021–0.015, IVW and the weighted median). Other than ICVF in
SLF, no significant reverse effects of these neuroimaging pheno-
types on depression were found (p for MR ranged from 0.860 to
0.498). For the above significant effects, ICVF in SLF and FMa
both showed significant heterogeneity among genetic instru-
ments, indicating potential horizontal pleiotropy (pFDR for Q test:
0.018–0.011, for MR-Presso global test: 0.024–0.009), and after
removing outlying genetic instruments, MR-Presso became
insignificant for both variables (β: −0.086 to −0.087, p for MR:
0.090–0.081). No other test showed significant horizontal pleio-
tropy or single-nucleotide polymorphism (SNP) heterogeneity
(pFDR for MR-Egger intercept > 0.071, pFDR for all Q tests > 0.135
and pFDR for MR-Presso global test > 0.214).
Conversely, the directional effect of neuroimaging phenotypes
on depression was then tested. The only significant effect was
shown from general variance of ICVF in association fibres to
depression for IVW method (gICVF-AF; β=−0.031, pFDR for
MR= 0.018); however, results using other MR methods were not
significant (pFDR for MR > 0.886). Heterogeneity tests were also
highly significant (pFDR= 4.78 × 10−7 for Q test and 3.33 × 10−4
for MR-Presso global test). Two other neuroimaging phenotypes
showed nominally significant effects on depression, including
higher MD in the ATR for MR-Egger (tMD-ATR; β= 0.107, p for
MR-Egger= 0.028, pFDR= 0.166; however, the Egger intercept
was not significant, pFDR= 0.432, Supplementary Fig. 11, Sup-
plementary Data 6 and Supplementary Table 3) and ICVF in SLF
(tICVF-SLF; β=−0.025, p= 0.030, pFDR= 0.179 for IVW).
An additional test was conducted to see whether there was a
substantial reduction in effect sizes after controlling for depressive
symptoms (assessed online by CIDI short form and PHQ-9, and
PHQ-4 for current symptoms along with the imaging assess-
ment), and all three white matter microstructural measures were
found significant in the MR analysis as the causal consequences of
depression showed large reductions in effect sizes (reduced by
20.5–30.9%), however, resting-state fluctuation amplitude in
Salience Network did not show such a reduction (by 0.3%, see
Supplementary Figs. 12–14).
In addition to the above MR results, genetic correlations were
found between depression and FA in forceps minor (rg=−0.157,
pcor for genetic correlation= 0.001), MD in ATR (rg= 0.106, pcor
for genetic correlation= 0.012), MD in cingulate part of
cingulum (rg= 0.105, pcor for genetic correlation= 0.012), MD
in forceps minor (rg= 0.119, pcor for genetic correlation= 0.012),
general ICVF in association fibres (rg=−0.083, pcor for genetic
correlation= 0.026), ICVF in cingulate part of cingulum (rg=
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Fig. 3 Results for replication analysis. a Comparisons of effect sizes for the discovery and replication samples. The x axes represent the mean standard
effect size across depression-PRS at all eight p thresholds for generating depression-PRS (pT). Colours for the bars indicate their categories (from top to
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−0.10, pcor for genetic correlation= 0.023), SLF (rg=−0.10, pcor
for genetic correlation= 0.023) and uncinate fasciculus (rg=
−0.10, pcor for genetic correlation= 0.023) (see Supplementary
Table 4).
Mediation analyses on imaging phenotypes. In the first med-
iation model, we tested whether polygenic risk of depression led
to changes in several neuroimaging variables through the med-
iating effects of depression. The neuroimaging variables were
chosen if they presented as a significant causal consequence of
depression in the MR analyses. Conversely, in the second model
the neuroimaging variable of MD in ATR showed a potentially
causal effect on depression at nominal significance using MR and
was therefore tested for its potential role as a mediator of genetic
risk on depression. Other neuroimaging variables nominally
significant in the MR analysis as causal factors were not tested as
mediators, because the heterogeneity tests were highly significant.
Here we report the results for depression-PRS at the threshold of
pT < 1. For other depression-PRS thresholds, see Supplementary
Data 8. Details can be found in Supplementary Methods.
We found evidence that current depressive symptoms
measured by PHQ-4 mediated the effect of depression-PRS on:
global MD (gMD-Total; β= 0.002, pFDR for mediation test=
0.003) and MD in thalamic radiations (gMD-TR; β= 0.002, pFDR
for mediation test= 0.001). Conversely, a significant mediation
effect of MD in ATR was found, mediating the effect of
depression-PRS on current depressive symptoms (PHQ-4) (β=
0.001, p for mediation test= 0.005). All significant mediation
models showed good model fit characteristics (CLI ranged
from 0.987 to 0.993, TLI ranged from 0.978 to 0.989, and all
pRMSEA= 1). A full list of results for all mediation models tested
can be found in Supplementary Data 8.
G-by-E interaction. Environmental variables that showed sig-
nificant interaction with depression-PRS included childhood
trauma, Townsend Index and recent stressful life events. The
dependent variables that provided evidence of G × E were mainly
measures of mental health, including depressive symptoms and
the self-declared total number of psychiatric conditions (see Fig. 6
and Supplementary Fig. 15, pFDR for linear regression <0.040).
In general, the effect of depression-PRS was enhanced in
participants exposed to more adverse social/socioeconomic
environments. In participants who reported any childhood
trauma versus none, the variance in the dependent variables
accounted for by depression-PRS were 1.67–1.78 times higher for
the total number of psychiatric conditions and affective
symptoms of depression. For participants in the most deprived
tertile band, variance explained in the sum of psychiatric
conditions was 3.57 times higher than for the least deprived
participants. Detailed reports can be found in Fig. 6, Supple-
mentary Fig. 15 and Supplementary Data 9–14.
We found no evidence of interactions however between
depression-PRS and adulthood trauma, recent stressful life events
and household income (pFDR for linear regression >0.086).
Discussion
Replicated associations between depression-PRS, behavioural and
neuroimaging phenotypes were found in the present study using
an independent imaging cohort. The strongest associations were
found between depression-PRS and mental health variables.
Several novel associations were detected, including associations
between depression-PRS and both brain white matter micro-
structure and a measure of resting-state activity amplitude. In
addition, MR analysis also showed evidence for changes in the
MD of thalamic radiations and global variance of MD that,
should the assumptions of MR hold, are likely to be a causal
consequence of depression. Other associations with higher poly-
genic risk included more abnormal self-reported sleep problems,
smoking behaviour and presence of cardiovascular conditions, as
well as an increased in body mass index. Findings regarding the
interactions of early-life factors and sociodemographic variables
with depression-PRS revealed that the effect of depression-PRS
Neuroimaging phenotypes to depressionDepression to neuroimaging  phenotypes
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Fig. 5 Mendelian Randomisation analysis between neuroimaging phenotypes and depression. The left panel shows the model and results for Mendelian
Randomisation results for the causal effect of depression to neuroimaging phenotypes, and the right panel shows the model and results for effect of
neuroimaging phenotypes to depression. For the model illustrations, G= genetic instruments extracted from GWAS summary statistics of the exposure,
E= exposure variable, O= outcome variable, U= unmeasured confounders (have no systematic association with G). In the scatter plots, x axes represent
−log10-transformed p values for the Mendelian Randomisation results, and the y axes represent the neuroimaging traits tested in the models. Three types
of dots represent the three Mendelian Randomisation methods used. Dashed grey lines are the p= 0.05 threshold for nominal significance. MD mean
diffusivity, ICVF intra-cellular volume fraction, TR thalamic radiations, SLF superior longitudinal fasciculus, Amplitude.N14 (SN) fluctuation amplitude in
Node 14 (i.e. the Salience Network).
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on mental health was stronger in participants who reported
childhood trauma and experienced socioeconomic deprivation.
While replicated associations were found between depression-
PRS and both behavioural and neuroimaging variables, in total
24.4% of all the behavioural phenotypes tested were found to be
significantly associated with depression-PRS. The proportion was
lower for the neuroimaging phenotypes tested, where only 7.6%
of the variables were significantly associated. The higher pro-
portion of associations found for behavioural phenotypes likely
reflects the overlapping genetic architecture of multiple psychia-
tric conditions with one another and the behavioural traits with
which they are commonly associated. In contrast, although sev-
eral brain phenotypes were associated with depression PRS, our
findings suggest that depression shares its genetic architecture
with only a small proportion of them. One potential reason for
this finding is a relative lack of signal in the GWAS of neuroi-
maging variables22. It is also possible that depression may have a
relatively specific relationship with a smaller number of neuroi-
maging variables, reflecting the underlying mechanisms of
depression.
Novel associations were found between depression-PRS and
neuroimaging variables on structural connectivity and functional
resting-state fluctuation amplitude in the brain. Findings from
both diffusion tensor imaging and resting-state data revealed the
importance of the prefrontal cortex, which is a hub for emotion
regulation and executive control23,24. The role of the prefrontal
cortex is further supported by a GWAS on depression in UK
Biobank, which showed the enrichment of risk-associated genes
in this region25. In particular, white matter microstructure
showed the largest effect sizes among brain phenotypes in our
results, and most trait associations in this category were replicated
in an independent data set. The current findings therefore indi-
cate a potentially risk-conferring role for white matter over other
modalities. This finding is supported by previous evidence that
white matter microstructure has stronger phenotypic associations
with lifetime depression compared to brain structural volumes26
and higher SNP heritability (20–60%) compared with other
neuroimaging modalities, indicating a greater genomic con-
tribution to individual differences in phenotypes27. Resting-state
findings were comparatively less replicated than for white matter,
which may be due to the less well-standardised protocols for
resting-state acquisition. For example, although others have
shown that the results of resting-state studies are broadly com-
parable across a range of acquisition lengths28, the data acquisi-
tion time for resting-state data in UK Biobank was relatively short
compared with other imaging cohorts, such as the Human
Connectome Project29.
The strongest replicated white matter finding with PRS were
found for the MD measures, consistent with previously reported
depressive symptom associations30. This may due to MD’s greater
sensitivity to ageing and related pathophysiological processes in
this mid- to late-life UK Biobank sample31. Alternatively, the
associations with dispersion density suggest that reductions in
MD may be partly due to reduced neurite density. This highlights
the need for further investigation of these issues in tissue from
large samples of depressed individuals. Recent gene expression
studies suggest that genetic predisposition to depression may
influence more spatially and functionally specific, neuronal-level
activities such as synaptic pruning and the overproduction of
synapses32 for regional segregation33 during the process of brain
maturation and myelin repair, which contribute largely to brain
structural and functional individual variance27. These highly
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regional and functionally specific brain phenotypes are of great
importance and may help explain how genetic predisposition
contributes to variance in neuroimaging measures.
Several associations between polygenic risk of depression and
neuroimaging variables were subsequently identified, through MR
analysis, to have directional or potential causal significance.
Whether brain structural and functional alterations are the out-
come or cause of depressive symptoms has long been debated34.
Our results show that some brain structural and functional
alterations are likely to be an outcome of depression; however,
whether other imaging features are also a cause is yet unclear.
Although our results for the causal effect from neuroimaging
phenotype to depression were null, therefore suggesting a possibly
uni-directional relationship from depression to the brain, it may
be premature to draw confident conclusions without the avail-
ability of a greater number of genome-wide significant genetic
instruments for neuroimaging traits. It is important to consider
that the relative lack of genome-wide significant loci for most
neuroimaging measures provides weaker genetic instruments for
MR, which may reduce power to detect causal associations. There
is currently a global effort to conduct GWAS using neuroimaging
phenotypes, and these efforts are likely to provide stronger
genetic instruments for future analyses. Further, white matter
microstructure in ATR did demonstrate a nominally significant
causal effect on depression, but notably not in the reverse
direction (from depression to ATR). This is in spite of the reverse
direction of testing (from depression to ATR) having a much
larger set of genetic instruments and greater power to detect
significant effects. This indicates that the white matter micro-
structure in ATR may be one of the strongest neuroimaging
candidates as a causal mediator of risk for depression.
The associations found in behavioural traits with depression-
PRS suggest that polygenic risk of depression may also identify a
predisposition to experience particular environmental risk expo-
sures, or a vulnerability to their effects and later recall. First, the
linear association of depression-PRS with sleep, recent pains,
smoking behaviour and the presence of any heart/cardiovascular
conditions showed the largest effect sizes. Various mechanisms
can be involved in these behavioural patterns, such as hyper-
activity in the hypothalamic–pituitary–adrenal (HPA) axis35, and
neurodevelopmental or parental impact on poorer health. Studies
have shown that poor physical and neurobiological health may be
correlated36. Here we identified candidate behavioural and phy-
sical phenotypes that may partially explain the genetic association
between depression and brain phenotypes for future research to
explore. Second and more directly, the environmental risk factors
tested in this study consistently strengthened the effect of
depression-PRS. Compared with previous studies that test
genetic–environment (G × E) interactions, the present study
revealed that the G × E effect can present on a whole-genome,
polygenic level. It may be a manifestation of interactions between
the environmental risk factors and some important endopheno-
types (e.g. HPA-axis activity) that polygenic risk of depression
confers upon.
There are several strengths and limitations to the present study.
PheWAS aims to identify the multiple phenotypes associated with
a single risk score. This is arguably a stronger approach than
studies that consider a single trait, based on prior theory, as
PheWAS is less constrained by prior assumptions based on an
incomplete understanding of disease mechanisms. Genotype-
based PheWAS approaches also have the considerable advantage
that they are based on robust biological knowledge that is fixed
from birth and less susceptible to reverse causality. The current
study leveraged the most up-to-date GWAS findings in depres-
sion, providing the most predictive PRS for depression with >100
instruments to test for bi-directional causal associations with
brain imaging variables, and improved power for the detection for
significant G × E interactions. This approach led to a number of
novel findings, including MR-based evidence for a causal effect of
depression on measures of brain function and connectivity. The
current data set has considerable advantages in terms of its large
sample size and was focussed on whether polygenic associations
can be replicated across neuroimaging samples, improving on an
area of previously identified methodological weakness37. Most
neuroimaging studies have sample sizes in the range of 50–100
people38. In contrast, the current study provided results from a
larger sample using a potentially less biased, data-driven
approach.
The present study uses MR to address causal relationships
between depression and brain imaging measures. The directional
or causal relationship between these traits has remained uncer-
tain. Our approach takes a more methodologically consistent
approach and applies state-of-the-art causal inference methods to
go beyond mere association, prioritising brain regions and risk
factors for experimental approaches.
Although we found robust and replicated associations between
brain measures and genetic risk of depression, whether neuro-
developmental or neurodegenerative factors are both contributing
to the individual differences is unknown. Participants in this
study were in their mid-life to later life. Various factors, including
ageing39, the long-term effects of early developmental deficits40
and comorbid illnesses, may impact variation in brain phenotypes
in this age range. These possible explanations necessitate long-
itudinal imaging data and studies of high-risk participants that
are able to identify the timing and trajectory of brain differences
before and after the onset of illness. The genomic regions driving
the shared architecture between depression and the brain phe-
notypes have also not been identified.
The mediation models employed in our investigation were
limited in that they tested for causal associations using cross-
sectional, rather than longitudinal, data. In order to make causal
inferences, we sought consistent findings using both of these
methodologies but acknowledge that other methodologies will
help to facilitate more robust causal inferences in future. Larger
samples for genetic studies on neuroimaging traits would largely
benefit such analysis in order to balance the statistic power of
clinical and neuroimaging phenotypes.
Future studies that provide improved GWAS on depression
and relevant traits would further increase our understandings of
depression. Summary statistics we used here were based on
GWAS that included some cases identified by self-declared
depressive symptoms. As it has been argued in previous papers,
the self-declared phenotypes may, to some extent, be more lenient
than clinically identified traits; however, the statistic power can
largely overcome the noise introduced by a small amount of
misclassification, which was supported by a high genetic corre-
lation between self-declared depression and clinically validated
depression5,6. While PRS is a powerful means of identifying
factors associated with genetic risk, it currently explains around
1.6% of phenotypic variance in depression. Future PRS scores,
trained on more precise GWAS summary statistics, are likely to
be more strongly predictive and may have greater sensitivity to
detect disease-relevant phenotypes. Further associations may be
revealed as PheWAS studies increase in size, although this is
counterbalanced by their small effect sizes and likely limited
clinical utility for individual patients.
To conclude, a novel and relatively unconstrained approach
was used to test for associations between depression-PRS and
various behavioural and neuroimaging variables of likely rele-
vance for depression. The findings revealed that white matter
microstructure, general mental and physical health and beha-
viours such as sleep patterns and smoking behaviour were
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associated with PRS of depression. Our findings suggest that most
neuroimaging associations with depression are likely to be the
causal consequence of depression.
Methods
Participants. Data from 21,888 individuals who participated in the UK Biobank
imaging study18 were included in the current study (released in 2 waves, in May
and October 2018, mean age is 62.75 years, standard deviation of age is 7.44 years,
48.4% were male, details can be found in Supplementary Table 5). The discovery
sample included participants mainly from the first data release, and the replication
sample from the second release (details for the discovery and replication samples
can be found in Supplementary Fig. 16). The majority of participants were assessed
at the Cheadle MRI site (80.1%) and the rest at the Newcastle site (19.9%). All
imaging data were collected using a 3-T Siemens Skyra (software platform VD13)
machine.
Behavioural and neuroimaging data acquisition were conducted under standard
protocols18,41. Written consent was acquired for all participants. Data acquisition
and analyses in the present study were conducted under UK Biobank Application
#4844. Ethical approval was accepted by the National Health Service (NHS)
Research Ethics Service (11/NW/0382).
Depression-PRS. In the present study, the sample used for generating GWAS
summary statistics is referred to as the training data set. The samples in which
depression-PRS were generated and tested are referred to as the testing samples,
which include both discovery and replication samples (as described above). We
removed any overlapping individuals from the training sample (used to estimate
allele effects for polygenic profiling) and testing data sets (where the effects of PRS
scores were estimated) (see Supplementary Methods).
PRS were calculated using the summary statistics from a meta-analysis of
depression GWAS from three cohorts, including PGC analysis of major
depression5, the 23andMe discovery sample in the Hyde et al. analysis of self-
reported clinical depression42 and a broad depression phenotype from UK Biobank
within individuals who had not participated in the imaging study25. This meta-
analysis provided a total training data set of 785,581 individuals (238,360 cases and
547,221 controls; for further details, see the study by Howard et al.6). We used the
summary statistics that included only the 8,099,819 SNPs that were present in the
GWAS data from all three cohorts6.
PRSice version 2.0 (used with PLINK 1.9)43 was used to calculate the
depression-PRS. Before the analyses were conducted, individuals who met the
following criteria were removed from the testing data set: related or non-European-
ancestry individuals and those who were included in PGC, 23andMe and UK
Biobank GWAS on depression (details can be found in Supplementary Methods).
The sample sizes reported below are after applying the above criteria. Genotyping
and quality control were conducted by UK Biobank as described in an earlier
protocol paper44. Details of SNP quality control and imputation can be found
in Supplementary Methods. We used the classic thresholding+clumping method to
generate PRSs. This method allows direct comparisons with a vast majority of
previous major depressive disorder (MDD)-PRS studies that used the same
approach. We did not consider some new Bayesian methods because they showed
no particular advantages over the thresholding+clumping method for MDD45.
Eight p value thresholds were applied to select genetic variants included in
calculating PRS, as p < 0.0005, p < 0.001, p < 0.005, p < 0.01, p < 0.05, p < 0.1, p < 0.5
and p < 1.
Behavioural phenotypes. The behavioural phenotypes consisted of 6 broad
categories, containing 209 variables in total. Where summary data were available
(e.g. neuroticism total score), the individual items used to derive the summary data
were not included. Phenotypes that were available on <2000 people in the discovery
sample were also excluded from further analysis. Mean sample sizes for all traits
contained in each category are included in brackets below. For further details see in
Table 1, Supplementary Table 1 and Supplementary Data 1. Categories included:
(1) Mental health (Ndiscovery= 7970 and Nreplication= 3880), including self-reported
symptoms of major psychiatric conditions46. In this category, three definitions for
depression were included: broad depression, which was a self-declared definition of
whether the participant had seen a psychiatrist for nerves, anxiety, tension or
depression6,25, probable depression which was derived from an abbreviated set of
self-declared symptoms of major depression and hospital admission history47, and
CIDI depression, a measure assessing full diagnostic criteria for depression based
on questions from a shortened version of the structured CIDI46. (2) Socio-
demographic measures (Ndiscovery= 8759 and Nreplication= 4352), such as house-
hold income and educational attainment. (3) Early-life risk factors (Ndiscovery=
9755 and Nreplication= 10,370), containing physical measures such as birth weight,
and environmental variables like adoption and maternal smoking. (4) Lifestyle
measures (Ndiscovery= 9231 and Nreplication= 4796), which mainly included items
on sleep, smoking, alcohol consumption and diet, (5) Physical measures (Ndiscovery
= 8961 and Nreplication= 4618), consisting of self-declared medical conditions such
as recent pains, cancers, operations, heart and artery diseases and other major
illnesses and also measures of blood pressure, arterial stiffness and hand-grip
strength, and finally (6) Cognitive ability (Ndiscovery= 8153 and Nreplication= 4105).
T
ab
le
1
A
su
m
m
ar
y
of
ph
en
ot
yp
es
.
C
at
eg
or
y
N
um
be
r
of
tr
ai
ts
N
fo
r
D
is
co
ve
ry
sa
m
pl
e
N
fo
r
R
ep
lic
at
io
n
sa
m
pl
e
U
K
B
io
ba
nk
da
ta
m
od
al
it
y
M
en
ta
l
he
al
th
4
4
R
an
ge
:
32
9
9
–1
0
,6
74
;
M
ea
n:
79
70
R
an
ge
:1
51
9
–5
56
5;
M
ea
n:
38
8
0
T
ou
ch
sc
re
en
,O
nl
in
e
fo
llo
w
-u
p
So
ci
od
em
og
ra
ph
ic
5
R
an
ge
:8
0
54
–9
9
4
1;
M
ea
n:
8
75
9
R
an
ge
:3
8
24
–5
19
9
;
M
ea
n:
4
35
2
T
ou
ch
sc
re
en
Ea
rl
y-
lif
e
ri
sk
fa
ct
or
11
R
an
ge
:
74
28
–1
0
,6
74
;
M
ea
n:
9
77
5
R
an
ge
:8
25
5–
11
,2
14
;
M
ea
n:
10
,3
70
T
ou
ch
sc
re
en
,O
nl
in
e
fo
llo
w
-u
p
Li
fe
st
yl
e
m
ea
su
re
s
6
6
R
an
ge
:
27
8
9
–1
0
,6
74
;
M
ea
n:
9
23
1
R
an
ge
:1
39
2–
55
6
5;
M
ea
n:
4
79
6
T
ou
ch
sc
re
en
Ph
ys
ic
al
m
ea
su
re
s
6
7
R
an
ge
:
21
55
–1
0
,6
74
;
M
ea
n:
8
9
6
1
R
an
ge
:1
0
4
7–
55
6
5;
M
ea
n:
4
6
18
T
ou
ch
sc
re
en
C
og
ni
tiv
e
ab
ili
ty
16
R
an
ge
:
52
50
–1
0
,6
74
;
M
ea
n:
8
15
3
R
an
ge
:2
58
6
–5
56
5;
M
ea
n:
4
10
5
T
ou
ch
sc
re
en
,O
nl
in
e
fo
llo
w
-u
p
In
tr
ac
ra
ni
al
/s
ub
co
rt
ic
al
vo
lu
m
e
9
R
an
ge
:
10
,6
27
–1
0
,6
31
;
M
ea
n:
10
,6
31
R
an
ge
:5
55
0
–5
55
3;
M
ea
n:
55
53
Br
ai
n
im
ag
in
g
W
hi
te
m
at
te
r
hy
pe
ri
nt
en
si
ty
8
9
70
2
51
8
7
Br
ai
n
im
ag
in
g
W
hi
te
m
at
te
r
m
ic
ro
st
ru
ct
ur
e
9
5
R
an
ge
:
9
34
1–
9
39
6
;M
ea
n:
9
37
7
R
an
ge
:5
18
7–
52
6
1;
M
ea
n:
52
39
Br
ai
n
im
ag
in
g
R
es
tin
g-
st
at
e
fu
nc
tio
na
l
co
nn
ec
tiv
ity
21
0
9
74
5
52
4
1
Br
ai
n
im
ag
in
g
R
es
tin
g-
st
at
e
fl
uc
tu
at
io
n
am
pl
itu
de
21
9
74
5
52
4
1
Br
ai
n
im
ag
in
g
A
to
ta
l
of
20
9
be
ha
vi
ou
ra
l
ph
en
ot
yp
es
(6
ca
te
go
ri
es
)
an
d
34
3
ne
ur
oi
m
ag
in
g
va
ri
ab
le
s
(4
ca
te
go
ri
es
)
ar
e
in
cl
ud
ed
.
W
he
re
th
er
e
ar
e
m
ul
tip
le
sa
m
pl
e
si
ze
s
in
a
ca
te
go
ry
,
a
ra
ng
e
an
d
th
e
m
ea
n
of
sa
m
pl
e
si
ze
s
(N
)
ar
e
pr
es
en
te
d.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16022-0
10 NATURE COMMUNICATIONS |         (2020) 11:2301 | https://doi.org/10.1038/s41467-020-16022-0 | www.nature.com/naturecommunications
This included four tests conducted at the assessment centres, four tests conducted
online and a general measure46 derived based on the tests conducted at the
assessment centres that have larger sample sizes (see more details in Supplementary
Methods).
All of the behavioural phenotypes, with the exception of mental health items
derived from online follow-up questionnaires (see Table 1), were primarily
acquired at the same time as the imaging assessment. Missing data for the imaging
assessment were imputed using data available from the baseline assessment. The
mean age difference between imaging assessment and the initial visit was 8.53 years
(SD= 1.56 years). Sample sizes and descriptions for all the behavioural phenotypes
can be found in Supplementary Data 1.
Neuroimaging phenotypes. Neuroimaging data consisted of: (1) intracranial and
subcortical volumes (Ndiscovery= 10,631 and Nreplication= 5553), containing eight
major structures46; (2) T2 flair imaging for the whole brain (Ndiscovery= 9829 and
Nreplication= 5472) and in subcortical regions (Ndiscovery= 9702 and Nreplication=
5187), which assess plausible white matter hyperintensity, (3) white matter
microstructure, indexed by FA, MD, neurite density (ICVF), isotropic volume
fraction and orientation dispersion index (Ndiscovery= 9377 and Nreplication= 5239)
for measures of white matter microstructure, in which we included three measures
of association, projection and thalamic radiation subsets, and 15 major individual
white matter tracts26; (4) pair-wise resting-state functional (rsfMRI) connectivity
(Ndiscovery= 9745 and Nreplication= 5241) of 21 nodes over the whole brain28; and
finally (5) the amplitude of low-frequency rsfMRI signal fluctuation of the 21 nodes
(Ndiscovery= 9745 and Nreplication= 5241). All four types of neuroimaging data
consisted of the imaging-derived phenotypes provided by UK Biobank. Available
data for the Hariri faces/shapes emotion task included only whole-brain activation
measures and a single region of interest (amygdala). We decided to exclude this
sparse data from our analyses until more comprehensive measures become avail-
able. Images were acquired, pre-processed and quality controlled by UK Biobank
using the FMRIB Software Library packages by a standard protocol (URL: https://
biobank.ctsu.ox.ac.uk/crystal/docs/brain_mri.pdf), which was also described in two
protocol papers18,48. All pilot study data with inconsistent scanner settings and
data that did not pass the initial quality assessment conducted by UK Biobank
imaging team were not included in the analysis. All imaging data were collected
using a 3-T Siemens Skyra (software platform VD13) machine. For clarity, major
steps of pre-processing are described in Supplementary Methods.
Statistical models for PheWAS. The GLM function in R (R version 3.2.3 and
version 3.3.2, RStudio version 0.98.1080) was used to test the PheWAS associa-
tions49, and the LME function from the ‘nlme’ package (version 3.1.131 under R
version 3.2.3) in R50 was used to test bilateral brain structures where hemisphere
was included as a within-subject variable. Depression-PRSs were set as independent
fixed effects, and behavioural and neuroimaging phenotypes were set as dependent
variables. Overall, 552 phenotypes (209 behavioural phenotypes+ 8 white matter
hyperintensity measures+ 9 intracranial/subcortical volumes+ 95 diffusion tensor
imaging measures+ 210 rsfMRI connectivity+ 21 rsfMRI fluctuation ampli-
tude) × 8 depression-PRS (under 8 p thresholds)= 4416 tests across phenotypes
and depression-PRS p thresholds were corrected altogether by FDR-correction51
using p.adjust function in R (q < 0.05).
Covariates included in all association tests were sex, age, age2, the first 15
genetic principal components and genotyping array25. For the replication analysis,
MRI site was added in addition to the above covariates for all association tests. In
addition to these covariates, adjustments were made for other confounders that
were relevant to each phenotypic category, as listed below. Scanner positions on the
x, y and z axes were included in the models for all brain phenotypes to control for
static-field heterogeneity38. Mean head motion was set as a covariate for the rsfMRI
data28,52. Subcortical volumetric tests controlled for intracranial volume26,53.
Hemisphere was controlled for where applicable in bilateral brain structural
phenotypes26. A list of covariates for each type of phenotype can be found in
Supplementary Table 1. Distributions of PRS using different covariates can be
found in Supplementary Fig. 17.
In order to help compare the results of logistic and linear regression models, we
report the standardised regression coefficients for the models as effect sizes (β) for
both types of models. Log-transformed odds ratio for binary dependent variables
using logistic regression models are therefore reported. FDR-corrected p values are
reported throughout. For clarity, we have also reported the number of associations
found using Bonferroni correction as a supplementary method. We acknowledge
that as the phenotypes are likely to be correlated, and therefore Bonferroni
correction is considered overly conservative. When effect sizes of different signs
were presented together, we reported the range of absolute effect sizes. Two-side
statistical tests were applied in all analyses.
Replication analysis for PheWAS. Traits that were found to be significantly
associated with depression-PRS at a minimum of four PRS variant p thresholds
were selected for re-analysis in the independent replication sample. Our decision to
combine FDR correction and four-threshold criterion was to control for type I
error in the first step (achieved by FDR correction) and to carry the most robust
and stable findings significant in more than half of all PRS thresholds to the
following MR and mediation analyses. This rationale is in line with studies on
depression itself (depression-PRS predicting depression), whereby similar odds
ratios are typically reported across multiple PRS thresholds5,6. The replication
analysis was conducted on the selected traits across all eight depression-PRS
thresholds. Results were considered to be replicated where they showed an identical
direction of effect across discovery and replication samples and where the p value
for the replication sample analysis was significant after correction for multiple
testing for depression-PRS at a minimum of four p thresholds. FDR correction was
applied to all the tests conducted in the replication analysis across all traits and p
thresholds (e.g., if m traits were taken into replication analysis, then p value
adjustment was applied to all m × 8 thresholds). The number of associations found
using Bonferroni correction was also reported for clarity.
Bidirectional MR analyses on depression and neuroimaging variables. We
used the ‘twosampleMR’ package version 0.4.22 in R to conduct bidirectional two-
sample MR analyses between depression and neuroimaging variables in order to
test for causal effects54. MR uses genetic data as instruments for testing whether
there is any causal effect between an exposure and an outcome variable. A chart
illustrating the underlying models can be found in Fig. 5, a flow chart of all the
steps in Supplementary Fig. 18 and the main procedure is summarised below.
GWAS summary statistics for depression came from the meta-analysis used to
generate the PRS as described above. For the neuroimaging variables, the ones that
were found associated with depression-PRS in both the discovery and replication
samples were chosen. GWAS were conducted using BGENIE version 355 on these
neuroimaging variables in the UK Biobank imaging sample that were used in the
PheWAS. Therefore, all exclusion criteria, genetic data quality check, ancestry
control, relatedness removal and covariates remain the same as the depression
GWAS. Overlapping individuals between the depression GWAS and the
neuroimaging GWAS were removed. The neuroimaging variables were scaled to
Mean= 0, SD= 1 to obtain standardised estimates. SNP heritability of depression
and number of genome-wide significant hits are reported elsewhere6. SNP
heritability of white matter microstructure measures estimated using linkage
disequilibrium (LD) score regression56 ranged from 13.2% to 34.0% and resting-
state fluctuation amplitude ranged from 13.8% to 14.5%. The number of genome-
wide significant loci (p < 5 × 10-8) ranged from 2 to 14 for all neuroimaging
phenotypes. More details of neuroimaging GWAS summary statistics can be found
in Supplementary Table 4.
To test the causal effect of depression on neuroimaging variables, genetic
instruments were chosen from the GWAS summary statistics of depression6, at a p
threshold of 5 × 10−8. These SNPs were then clumped with a distance of 3000 kb
and a maximum LD r2 of 0.001, resulting in 107 independent genetic instruments.
These SNPs were then identified within the GWAS summary statistics for each
outcome, and those that were not present in both GWAS data sets were removed.
SNP effect data on both the exposure and outcome were then harmonised to match
the effect alleles before conducting the MR analyses.
For the causal effects of neuroimaging variables on depression, genetic
instruments were chosen at a p threshold of 8 × 10−6, as the smallest number of
genome-wide significant hits for neuroimaging GWAS was 2 prior to harmonising
the two GWAS summary statistics. We therefore chose this lower threshold for
neuroimaging GWAS to select genetic instruments. The same approach has been
used in a previous MR study57. Genome-wide significant SNPs for depression and
relevant genes have been reported and discussed by Howard et al.6. For significant
MR results showing effects from neuroimaging variables to depression, we
conducted manual inspections on scatter plots to ensure that the top neuroimaging
GWAS SNPs driving the results were indeed brain relevant by checking if they have
been associated gene expression in neural tissues or associated with other
psychiatric or brain phenotypes in previous studies. SNPs that appear anomalous
are reported in “Results” and highlighted in “Discussion”. Genetic instruments
used in the bidirectional MR analyses are reported in Supplementary Data 7 and
Supplementary Table 3. At this threshold, after clumping with the same parameters
as for choosing genetic instruments for depression, 12–44 independent genetic
instruments were identified for each neuroimaging variable (see Supplementary
Table 4). To further illustrate overlapping genetic architecture, we reported results
for LD score regression based on the summary statistics above.
Three robust MR methods were chosen: MR-Egger, IVW, and the weighted
median method. We also conducted three additional analyses (i) to test for
horizontal pleiotropy by estimating the MR-Egger intercept and to test global
heterogeneity of the genetic instruments using (ii) the Q test54 and (iii) the MR-
Presso global test (using R package ‘MRPRESSO’ version 1.0)58. Four types of plots
were generated for visual inspection: (1) leave-one-out plot for testing SNP outliers,
(2) funnel plot to show horizontal pleiotropy, (3) forest plot showing single SNP
effects in the MR analysis, and finally, (4) scatter plot for overall inspection of effect
sizes in GWAS for the cause and outcome.
FDR corrections were applied separately on each MR method within each trait
category using a traditional whole-brain family-wise error correction as can be
widely seen in other neuroimaging studies59,60.
We have also provided results for genetic correlation using Linkage
Disequilibrium Score Regression v1.0.056 in the main text and phenotypic
association between depressive symptoms and other variables in Supplementary
Table 4 and Supplementary Figs. 12–14 for completeness.
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Statistical models to test for the mediating effect of neuroimaging variables.
Following the PheWAS and MR analyses, we sought to test whether manifestations
of depression were mediating the causal effect of depression-PRS on brain imaging
phenotypes, as well as whether the neuroimaging variables act as neural mediators
of genetic risk on depressive traits (i.e. neuroimaging traits were ‘endophenotypes’).
These tests were applied using SEM with the ‘lavaan’ package version 0.5.23.1097 in
R v3.2.361. Two types of mediation analysis were conducted (Supplementary
Fig. 19). The first one aimed to test whether the neuroimaging effects were the
consequence of depression by testing whether depression mediated the relationship
between polygenic risk and neuroimaging variables (predictor= depression-PRS,
mediator variable= CIDI definition of depression/depressive symptoms and
dependent variables= neuroimaging traits). Neuroimaging variables were chosen
from those measures that showed a significant causal effect from depression in the
MR analyses. The second type of mediation models tested whether neuroimaging
variables mediated the relationship between polygenic risk of depression on
depressive phenotypes (predictor= depression-PRS, mediator= neuroimaging
traits and dependent variable= CIDI definition of depression/depressive symp-
toms). The list of mediators was restricted to the neuroimaging phenotypes that
showed significant causal effects on depression by MR analyses. For both types of
mediation analyses, variables for manifestations of depression include CIDI defi-
nition for depression, severity of depression assessed by CIDI short form62 and the
current symptoms at the imaging assessment measured by PHQ-463. In order to
maximise statistic power, all mediation tests used the full sample that included both
discovery and replication data sets (N= 21,888), adjusted for site.
All covariates remained the same as for PheWAS regression models. p Value
correction followed the same method as the MR analysis. Illustration for the
models can be found in Supplementary Fig. 1, Supplementary Data 8 and
Supplementary Methods.
Interactions of depression-PRS and early risk factors or sociodemographic
variables. Interactions between environmental variables, previously associated
with depression, and depression-PRS were tested. Environmental variables were
chosen from early-life risk factors and sociodemographic variables previously
found associated with risk for depression and showed depression case–control
difference in the present sample (p < 0.05), which include: household income,
Townsend Index, childhood trauma, adulthood trauma, and recent stressful life
events in the past 6 months before imaging assessment64,65. Additional tests on the
interaction effect between depression-PRS and sex were also reported in Supple-
mentary Data 14 for completeness.
Dependent variables were the behavioural and imaging phenotypes that had
significant associations with depression-PRS at a minimum of four thresholds in
both the discovery and replication samples. Variables that were selected as factors
were not included as dependent variables. The covariates included in these G × E
analyses were those included in the PheWAS analyses, plus the interaction terms
for PRS × covariates and environmental variables × covariates, in accordance with
previous studies66. FDR correction was applied in the same manner with the
PheWAS (m dependent variables × 8 p thresholds).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data used in the present study is available from UK Biobank with restrictions
applied. Data were used under license and thus not publicly available. Access to the UK
Biobank data can be requested through a standard protocol (https://www.ukbiobank.ac.
uk/register-apply/). The summary statistics of PGC_139k can be accessed from https://
doi.org/10.7488/ds/2458. A data transfer agreement is required for accessing the
23andMe_307k summary statistics for the GWAS of depression (https://
research.23andme.com/dataset-access/).
Code availability
All code used for data preparation and analysis are available upon request.
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